Tong Ren Tang Technologies CoTGRNF 50 ROE % is 1.59% as of Dec. 2025, which is 82% below its 10-year median of 8.77. GuruFocus rates TGRNF with a GF Score™ of 50/100 and a GF Value™ of $0.84 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 935 Drug Manufacturers companies, Tong Ren Tang Technologies Co ranks worse than 51.66% on this metric.
The historical rank and industry rank for Tong Ren Tang Technologies Co's ROE % or its related term are showing as below:
TGRNF'
s ROE % Range Over the Past 10 Years
Min: 5.47 Med: 8.77 Max: 14.84
Current: 5.47
During the past 13 years, Tong Ren Tang Technologies Co's highest ROE % was 14.84%. The lowest was 5.47%. And the median was 8.77%.
TGRNF's ROE % is ranked worse than 51.66% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs TGRNF: 5.47
Tong Ren Tang Technologies Co (OTCPK:TGRNF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Tong Ren Tang Technologies Co ROE % Related Terms
Tong Ren Tang Technologies Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tong Ren Tang Technologies Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's ROE % distribution charts can be found below:
* The bar in red indicates where Tong Ren Tang Technologies Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Tong Ren Tang Technologies Co (TGRNF) has a ROE % of 1.59% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Tong Ren Tang Technologies Co and its competitors. This is 82% below median its historical median of 8.77. Over the past decade, Tong Ren Tang Technologies Co's ROE % has ranged from 5.47 to 14.84. According to the industry distribution chart, Tong Ren Tang Technologies Co ranks #483 out of 935 companies in the Drug Manufacturers industry, placing it in the top 51.7%.
Is Tong Ren Tang Technologies Co's ROE % too high?
Tong Ren Tang Technologies Co's current ROE % of 1.59% is 82% below median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 5.47 to a high of 14.84. The Drug Manufacturers industry median ROE % is 6.00. Tong Ren Tang Technologies Co's value of 1.59% is 73.5% below this industry median. Based on the distribution chart, Tong Ren Tang Technologies Co ranks #483 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tong Ren Tang Technologies Co has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tong Ren Tang Technologies Co's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Tong Ren Tang Technologies Co ranks #483 out of 935 companies for ROE %. This places Tong Ren Tang Technologies Co in the lower half of its industry. The industry median ROE % is 6.00. Tong Ren Tang Technologies Co's value of 1.59% is 73.5% below this benchmark. Historically, Tong Ren Tang Technologies Co's own ROE % has ranged from 5.47 to 14.84 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 6.00, Tong Ren Tang Technologies Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tong Ren Tang Technologies Co's current ROE % of 1.59% is 73.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Tong Ren Tang Technologies Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tong Ren Tang Technologies Co's current ROE % is 1.59%, which is 82% below median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tong Ren Tang Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co (TGRNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.84, compared to a current price of $0.49 — trading 41.1% below its estimated fair value. The current ROE % is 1.59%, which is 82% below median its 10-year median of 8.77 and 73.5% below the Drug Manufacturers industry median of 6.00. Tong Ren Tang Technologies Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Tong Ren Tang Technologies Co (TGRNF), the current ROE % is 1.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tong Ren Tang Technologies Co (TGRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co stock appears to be undervalued.
The current stock price of $0.49 is trading 41.1% below its estimated GF Value™ of $0.84.
GuruFocus considers Tong Ren Tang Technologies Co to be Significantly Undervalued.
Key valuation signals for TGRNF:
ROE %: 1.59% (82% below median its 10-year median of 8.77)
GF Value™: $0.84 vs. price of $0.49 (41.1% below fair value)
Industry Position: 73.5% below the Drug Manufacturers median (#483 of 935)
No single metric tells the full story. See the TGRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tong Ren Tang Technologies Co Business Description
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
50GF Score
Get the complete analysis for TGRNF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGRNF has been successfully added to your 
